Aims: Although a dramatic increase has been observed in Turkish diabetic retinopathy (DR) patients due to the rising cases of diabetes mellitus (DM), ophthalmological advancements facilitate treatment for DM and its ophthalmic complications, such as proliferative diabetic retinopathy (PDR). To determine the effectiveness of the repeated anti-vascular endothelial growth factor (anti-VEGF) intra-vitreal injections (IVI or IVIs) on the macular vascular density (VD) in PDR.
Methods: This theme includes methodological research, retrospective validation studies, and multivariate meta-analysis. The data were obtained from the PubMed, Google Scholar, SCOPUS, WoS, and Google Academic Papers between 2004 and 2023. The injections which completed within 6 months, consecutively administered monthly for three times. This editorial involves diabetic cases that were previously injected with any of Anti-VEGF agent, particularly aflibercept, ranibizumab, and bevacizumab in PDR populace. They were selected over eighteen years who owned high-quality images of “optical coherence tomography angiography” (OCTA). The retinas of thirty-five sufferers from DR were bilaterally analyzed by utilizing keywords.
Results: The analysis of VD relevant to PDR did not identify notable alterations of TCP, DCP and SCP, central retinal vascular layers, both before and after the first anti-VEGF IVI cure. Similar events were detected by the consecutive second and third phases. Besides, central retinal thickness (CRT) decreased at least 10 % from the associated with control cases. Twenty eyes were cure-resistant, whereas fifteen eyes were medical care-responsive. Thirty-five humans with PDR were selected. The gender distribution in the study was sixty percent men and forty percent women, and their average age ranged between forty and eighty.
Conclusion: The article revealed that VD measures did not illustrate any expressive difference in TCP, DCP and SCP before and after three injections. In other words, the baseline VD measurements did not suggestively conclude while CRT was reducing slightly.
Anti-VEGF and PDR vessel density intra-vitreal anti-VEGF and VD in PDR anti-VEGF and macular VD in PDR proliferative diabetic retinopathy and anti-VEGF vascular macular modifications with anti-VEGF in PDR
DOSYASINI YOLLADIM
---
İLGİNİZ İÇİN TEŞEKKÜR EDER, SAYGILARIMI SUNARIM. AYHAN ÖNAL TEL: 507 2110304 E-MAIL: drayhanonal@yahoo.com
Birincil Dil | İngilizce |
---|---|
Konular | Göz Hastalıkları, Göz Hastalıkları ve Göz Ölçümleri (Diğer) |
Bölüm | Orijinal Makale |
Yazarlar | |
Yayımlanma Tarihi | 27 Ekim 2024 |
Gönderilme Tarihi | 11 Eylül 2024 |
Kabul Tarihi | 22 Ekim 2024 |
Yayımlandığı Sayı | Yıl 2024 Cilt: 7 Sayı: 6 |
Üniversitelerarası Kurul (ÜAK) Eşdeğerliği: Ulakbim TR Dizin'de olan dergilerde yayımlanan makale [10 PUAN] ve 1a, b, c hariç uluslararası indekslerde (1d) olan dergilerde yayımlanan makale [5 PUAN]
Dahil olduğumuz İndeksler (Dizinler) ve Platformlar sayfanın en altındadır.
Not: Dergimiz WOS indeksli değildir ve bu nedenle Q olarak sınıflandırılmamıştır.
Yüksek Öğretim Kurumu (YÖK) kriterlerine göre yağmacı/şüpheli dergiler hakkındaki kararları ile yazar aydınlatma metni ve dergi ücretlendirme politikasını tarayıcınızdan indirebilirsiniz. https://dergipark.org.tr/tr/journal/2316/file/4905/show
Dergi Dizin ve Platformları
Dizinler; ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, vs.
Platformlar; Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons vs.